tbuckley/cabot-search huggingface dataset:
Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Authors: Carolina A. Parada, Joshua W. Osbun, Tina Busald, Yigit Karasozen, Sumanpreet Kaur, Min Shi, Jason Barber, Widya Adidharma, Patrick J. Cimino, Catherine Pan, Luis F. Gonzalez-Cuyar, Robert Rostomily, Donald E. Born, Jing Zhang, Manuel Ferreira
Journal: Clinical Cancer Research (2019)

Most World Health Organization (WHO) grade I meningiomas carry a favorable prognosis. Some become clinically aggressive with recurrence, invasion, and resistance to conventional therapies (grade 1.5; recurrent/progressive WHO grade I tumors requiring further treatment within 10 years). We aimed to identify biomarker signatures in grade 1.5 meningiomas where histopathology and genetic evaluation has fallen short.Mass spectrometry (MS)-based phosphoproteomics and peptide chip array kinomics were used to compare grade I and 1.5 tumors. Ingenuity Pathway Analysis (IPA) identified alterations in signaling pathways with validation by Western blot analysis. The selected biomarker was evaluated in an independent cohort of 140 samples (79/140 genotyped for meningioma mutations) by tissue microarray and correlated with clinical variables.The MS-based phosphoproteomics revealed differential Ser/Thr phosphorylation in 32 phosphopeptides. The kinomic profiling by peptide chip array identified 10 phosphopeptides, including a 360% increase in phosphorylation of RB1, in the 1.5 group. IPA of the combined datasets and Western blot validation revealed regulation of AKT and cell-cycle checkpoint cascades. RB1 hyperphosphorylation at the S780 site distinguished grade 1.5 meningiomas in an independent cohort of 140 samples and was associated with decreased progression/recurrence-free survival. Mutations in NF2, TRAF7, SMO, KLF4, and AKT1 E17K did not predict RB1 S780 staining or progression in grade 1.5 meningiomas.RB1 S780 staining distinguishes grade 1.5 meningiomas, independent of histology, subtype, WHO grade, or genotype. This promising biomarker for risk stratification of histologically bland WHO grade I meningiomas provides insight into the pathways of oncogenesis driving these outlying clinically aggressive tumors.
Stimuli‐Responsive Hydrogels with Antibacterial Activity Assembled from Guanosine, Aminoglycoside, and a Bifunctional Anchor
Authors: Jingjing Hu, Qianyu Hu, Xu He, Cenxi Liu, Yanlong Kong, Yiyun Cheng, Yadong Zhang
Journal: Advanced Healthcare Materials (2019)

Abstract Multistimuli‐responsive hydrogels with specific functions have attracted great interest for biomedical applications; however, these smart hydrogels usually require the presynthesis of macromolecular building blocks with multiple ligands and the integration of bioactive cargoes into the gels. Here, a multistimuli‐responsive hydrogel with potent antibacterial activity by a combination of supramolecular assembly and iminoboronate chemistry is reported. The hydrogel consists of all‐small‐molecule building blocks including aminoglycoside, guanosine, potassium ion, and a bifunctional anchor bearing both boronic acid and aldehyde groups. Guanosines form quadruplexes in the presence of potassium ions via supramolecular assembly, and the bifunctional anchor connects aminoglycosides, a class of potent antibiotics to cis‐diol groups on quadruplexes via dynamic iminoboronate chemistry, yielding a smart hydrogel containing abundant antibiotics. The hydrogel is sensitive to multistimuli such as heat, acids, oxidants, glucose and crown ether, which promote the release of antibiotics from the gels. Moreover, the prepared hydrogels show potent antibacterial activities both in vitro and in vivo. The results provide a new option to prepare antibacterial hydrogels with multistimuli responsiveness via facile chemistry using all‐small‐molecule building blocks.
Can serum thioredoxin levels predict sensitivity to platinum in lung cancer?
Authors: Vy Thuy Dinh, Medhi Wangpaichitr, Dao M. Nguyen, Maria Matsangou, Chunjing Wu, Eugene Ahn, Niramol Savaraj
Journal: Journal of Clinical Oncology (2013)

e22062 Background: Our laboratory has found that cisplatin resistant lung cancer cells possess high levels of ROS (reactive oxygen species). Low intracellular TRX1 (thioredoxin) levels due to increased secretion of the thioredoxin-1 (TRX1) is the primary reason for high intracellular ROS levels. We have further shown that reconstituting TRX1 protein in cisplatin-resistant cells can restore sensitivity to cisplatin. Conversely, silencing TRX1 in parental cells reduced the sensitivity to cisplatin (MCT11:604, 2012). Thus, it is possible that serum TRX1 levels may be a useful marker to predict sensitivity to platinum containing regimens. Methods: Serum samples were obtained before, during, and after platinum chemotherapy. TRX1 was determined by sandwich ELISA with two TRX1 antibodies. Samples, standards, and reagent blank were incubated with precoated plate (IBL). Labeled antibody solution was added followed by Chromagen substrate and subjected to plate reader. The value on normal healthy individual is less than 5 ng/ml. The lowest limit of detection is 1 ng/ml. Results: 11 patients (pts) were entered into the study. 6 pts had small cell lung cancer (SCLC) and 5 had non small cell lung cancer (NSCLC). 2 SCLC pts died before treatment and couldn’t be assessed and 2 pts are too early to assess response. In these lung cancer pts, the baseline levels ranged from 0 to 96.5 ng/ml. Thus far, 4 pts (1 SCLC and 3 NSCLC) who had baseline TRX1 levels of 0, 0, 0 and 3 responded to chemotherapy. An additional SCLC pt with very high levels of TRX1 (96) also responded to chemotherapy. However, this pt also had a recent operation for NSCLC and the baseline blood sample was obtained after the operation, which may not be the appropriate baseline. 2 pts with baseline TRX1 levels of 31.1 and 6.5 did not respond to treatment. TRX1 levels increased during chemotherapy, especially when given concurrently with radiation. However, in pts who responded, TRX1 levels decreased at the end of treatment. Conclusions: The study is currently ongoing. Our initial results suggest that low TRX1 levels may indicate possible future response to platinum containing regimens. While TRX1 levels may increase during treatment, in pts who respond to treatment, TRX1 levels often decrease back to baseline.
WT1 Overexpression after Induction Therapy in Children AML Is Associated with Higher Risk of Relapse.
Authors: Annick Blaise, Hugues Leroy, Anne Auvrignon, Paola Ballerini, Helene Lapillonne, Christine Perot, Francoise Mazingue, Sylvie Fasola, Cyril Flamant, Luc Douay, Guy Leverger, Claude Preudhomme, Judith Landman-Parker
Journal: Blood (2004)
LRF/Pokemon Plays a Pivotal Role in B Versus T Lymphoid Lineage Fate Decision at the Early Lymphoid Progenitor Stage by Opposing Notch1 Signaling.
Authors: Takahiro Maeda, Taha Merghoub, Lin Dong, Manami Maeda, Robin Hobbs, Johannes Zakrzewski, Marcel van den Brink, Hirokazu Shigematsu, Koichi Akashi, Arthur Zelent, Julie Teruya-Feldstein, Giorgio Cattoretti, Pier Paolo Pandolfi
Journal: Blood (2006)
A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients
Authors: Feng Lu, Qian Zhou, Lu Liu, Guandi Zeng, Weimin Ci, Wanting Liu, Gong Zhang, Zhiyi Zhang, Peng Wang, Aiqun Zhang, Yunfei Gao, Lei Yu, Qingyu He, Liang Chen
Journal: Theranostics (2019)

Rationale: Effective targeting therapies are limited in Hepatocellular carcinoma (HCC) clinic. Characterization of tumor suppressor genes (TSGs) and elucidation their signaling cascades could shed light on new strategies for developing targeting therapies for HCC. Methods: We checked genome-wide DNA copy number variation (CNV) of HCC samples, focusing on deleted genes for TSG candidates. Clinical data, in vitro and in vivo data were collected to validate the tumor suppressor functions. Results: Focal deletion of GATA4 gene locus was the most prominent feature across all liver cancer samples. Ectopic expression of GATA4 resulted in senescence of HCC cell lines. Mechanistically, GATA4 exerted tumor suppressive role by orchestrating the assembly of a tumor suppressor enhancing module: GATA4 directly bound and potently inhibited the mRNA transcription activity of β-catenin; meanwhile, β-catenin was recruited by GATA4 to promoter regions and facilitated transcription of GATA4 target genes, which were TSGs per se. Expression of GATA4 was effective to shrink GATA4-deficient HCC tumors in vivo. We also showed that β-catenin inhibitor was capable of shrinking GATA4-deficient tumors. Conclusions: Our study unveiled a previously unnoticed tumor suppressor enhancing module assembled by ectopically expressed GATA4 in HCC cells and denoted a therapeutic opportunity for GATA4 deficient HCC patients. Our study also presented an interesting case that an oncogenic transcription factor conditionally functioned as a tumor suppressor when recruited by a TSG transcription factor.
Unrelated Donor Umbilical Cord Blood Transplantation (UD-UCBT) for Adult Patients with High-Risk Acute Lymphoblastic Leukemia (ALL).
Authors: Jaime Sanz, Ignacio Lorenzo, Pau Montesinos, Leonor Senent, Luis Larrea, Dolores Planelles, Guillermo Martin, Jose Cervera, Isidro Jarque, Javier de la Rubia, Guillermo Orti, Miguel Scaff, Mari Liz Paciello, Federico Moscardo, Monica Romero, Luis Benlloch Biologist, Miguel A. Sanz, Guillermo Sanz
Journal: Blood (2007)
Shining New Light on Long-term Ozone Harms
Authors: Vijay S. Limaye, Kim Knowlton
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
High Levels of Tumor Load Reduction after Intensive Chemotherapy Favorably Affect the Prognosis of BCR/ABL+ ALL Adult Patients Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.
Authors: G. Cimino, L. Elia, Fabrizio Pane, M. Vignetti, P. Fazi, S. Iacobelli, G. Meloni, A. Vitale, V. Martini, G. Martinelli, F. Di Raimondo, M. Bonifacio, F. Fabbiano, G. Saglio, M. Baccarani, R. Foà, F. Mandelli
Journal: Blood (2006)
Prognostic Significance of β-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.
Authors: Apostolia-Maria Tsimberidou, Hagop M. Kantarjian, Michael J. Keating, Susan O’Brien, Sijin Wen, Jorge Cortes, Francis Giles, Charles Asa Koller, Guillermo Garcia-Manero, Sherry Pierce, Mark Brandt, Emil J. Freireich, Elihu H. Estey
Journal: Blood (2006)
White (or rather clear) bile related to papillary stone impaction
Authors: Vincent Zimmer
Journal: Endoscopy (2019)

As a typical misnomer, “white bile” refers to a translucent, “clear” aspect of the bile fluid largely devoid of bilirubin and bile acids, and has traditionally been linked to malignant biliary obstruction [1]. By contrast, its occurrence in short-term, albeit high-grade biliary obstruction related to papillary stone impaction has not been specifically reported.
Yf-H-2015005, a New CXCR4 Antagonist, in the Mobilization of Hematopoietic Stem Cells in Patients with Non-Hodgkin Lymphoma: A Randomized-Controlled Phase 3 Study
Authors: Weiping Liu, Yufu Li, Quanshun Wang, Kaiyang Ding, Hang Su, Yue-rong Shuang, Sujun Gao, Hongmei Jing, Ye Chai, Dehui Zou, Hui Liu, Chunling Wang, Lihong LIU, Yicheng Zhang, Jinying Lin, Haiyan Zhu, Meixia Shang, Xiaoyan Yan, Chen Yao, Fengyuan Chang, Jun Zhu, Yuqing Song
Journal: Blood (2019)
The Relative Percentage of Recipient T (CD3+) and Activated Lymphocytes (CD25+) Allows to Predict the Dynamics of Chimerism and the Risk of Complications after Allogeneic Stem Cell Transplantation
Authors: Ismael Buno Borde, Cintia Manzano, Pascual Balsalobre, David Serrano, Gabriela Rodriguez Macias, Alfonso Gomez-Pineda, Jose L. Diez-Martin
Journal: Blood (2008)
Routine survey of <i>Mycobacterium tuberculosis</i> isolates reveals nosocomial transmission
Authors: Charlotte Genestet, Raphael Paret, Catherine Pichat, Jean-Luc Berland, Véronique Jacomo, Gerard Carret, Isabelle Fredenucci, Elisabeth Hodille, Jean-Philippe Rasigade, Sandrine Boisset, Anne Carricajo, Gérard Lina, Anne-Sophie Ronnaux-Baron, Jean-François Mornex, Jacqueline Grando, Agathe Sénéchal, Florence Ader, Oana Dumitrescu
Journal: European Respiratory Journal (2019)

<b>Tuberculosis is the number one life-threatening contagious disease. Ongoing systematic and prospective <i>M. tuberculosis</i> genotyping enables tracing transmissions, enhances active case finding and allows implementation of effective airborne control measures.</b>http://bit.ly/2OyJvKx
N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers: roles, mechanisms, and applications
Authors: Bin-bin Hu, Xiao-yan Wang, Xu-Yu Gu, Chen Zou, Zhen-jun Gao, Heng Zhang, Yu Fan
Journal: Molecular Cancer (2019)

Abstract Analogous to DNA methylation and histone modification, RNA modification, as another epigenetic layer, plays an important role in many diseases, especially in tumours. As the most common form of RNA modification, m 6 A methylation has attracted increasing research interest in recent years. m 6 A is catalysed by RNA methyltransferases METTL3, METTL14 and WTAP (writers), m 6 A is removed by the demethylases FTO and ALKBH5 (erasers) and interacts with m6A-binding proteins, such as YT521-B homology (YTH) domain-containing proteins. This article reviews recent studies on methylation modification of m 6 A in gastrointestinal tract cancers.
Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.
Authors: Grzegorz S. Nowakowski, Chin-Yang Li, David Dingli, Shaji Kumar, Morie A. Gertz, Martha Q. Lacy, John A. Last, Angela Dispenzieri, Philip R. Greipp, Steven Zeldenrust, Francis Buadi, Suzanne Hayman, Robert A. Kyle, Vincent S. Rajkumar
Journal: Blood (2007)
T Cells Demonstrate Enhanced Specificity for CD19+ Malignancies When Stimulated with IL-21.
Authors: Harjeet Singh, Mary Helen Huls, Margaret J. Dawson, Tiejuan Mi, Gianpietro Dotti, Dean A. Lee, Partow Kebriaei, Elizabeth J. Shpall, Perry B. Hackett, Carl H. June, Richard E. Champlin, Laurence J.N. Cooper
Journal: Blood (2008)
Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.
Authors: Jeanne Palmer, Timothy Goggins, Gloria Broadwater, Nelson J. Chao, John Chute, R. E. Coleman, Keith M Sullivan, Gwynn Long, Cristina Gasparetto, Anne Beaven, David Rizzieri
Journal: Blood (2008)
Deconstructing the Clonal Advantage and Clonal Stability of 5q- Candidate Genes in Del(5q) MDS on a Single Cell Level
Authors: Ursula S.A. Stalmann, Fabio Ticconi, Ronghui Li, Aaron B. Wong, Glenn Cowley, David E. Root, Dirk Heckl, Inge Snoeren, Sergio Martinez, Tim H Brümmendorf, Andreas Schuppert, Ivan Costa, Benjamin L. Ebert, Rebekka K. Schneider
Journal: Blood (2019)
Potential of Intra-arterial Urokinase After Incomplete Mechanical Thrombectomy—Looking Back, Moving Forward
Authors: Victor Lopez-Rivera, Sunil A. Sheth
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
In Vivo Modulation of T Cell and Monocyte Function Following Infusion of Mesenchymal Stromal Cells (MSC)
Authors: Cristina Castilla-LLorente, Mineo Iwata, Marco Mielcarek, V. Kraig Abrams, Billanna Hwang, Richard A. Nash, Beverly Torok-Storb
Journal: Blood (2008)
Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).
Authors: Mohamed Sorror, Michael Maris, Barry Storer, Brenda Sandmaier, Monic Stuart, Ute Hegenbart, Edward Agura, Thomas Chauncey, Jose Leis, Michael Pulsipher, Peter McSweeney, Jerry Radich, James Wade, Benedetto Bruno, Amelia Langston, Dietger Niederwieser, Karl Blume, Rainer Storb, David Maloney
Journal: Blood (2004)
Molecular recognition-directed site-specific release of stem cell differentiation inducers for enhanced joint repair
Authors: Xuemin Liu, Yunhua Chen, Angelina S. Mao, Chengkai Xuan, Zhifang Wang, Huichang Gao, Geng An, Ye Zhu, Xuetao Shi, Chuanbin Mao
Journal: Biomaterials (2019)
A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA
Authors: Lale Kostakoglu, Paola Berchialla, Federico Dalmasso, Larry A Pierce, Umberto Vitolo, Maurizio Martelli, Laurie H Sehn, Marek Trněný, Tina G Nielsen, Christopher R Bolen, Deniz Sahin, Calvin Lee, Tarec Christoffer C. El-Galaly, Federico Mattiello, Paul E Kinahan, Stephane Chauvie
Journal: Blood (2019)
Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.
Authors: Patrick J. Stiff, Ivana NM Micallef, Auayporn P. Nademanee, Edward A. Stadtmauer, Richard Thomas Maziarz, Brian J. Bolwell, Gary Bridger, Gary Calandra, Jennifer Angell, John F. DiPersio
Journal: Blood (2008)
CD3−cd(16+56)+ Cell Dose Is An Important Factor Determining Clinical Outcomes in Patients Undergoing Unmanipulated HLA-Identical Sibling Hematopoietic Stem Cell Transplantation
Authors: Xiaowen Tang, Biyun Peng, Mingqing Zhu, Wu Depei, Aining Sun, Changgeng Ruan
Journal: Blood (2008)
A population-based analysis of suicidality and its correlates: findings from the National Mental Health Survey of India, 2015–16
Authors: Senthil Amudhan, Gopalkrishna Gururaj, Mathew Varghese, Vivek Benegal, Girish Nagaraja Rao, David Vincent Sheehan, Arun Mahadeo Kokane, Bir Singh Chavan, Pronob Kumar Dalal, Daya Ram, Kangkan Pathak, Raj Kumar Lenin Singh, Lokesh Kumar Singh, Pradeep Sharma, Pradeep Kumar Saha, Chellamuthu Ramasubramanian, Ritambhara Yeshwant Mehta, Theerthankara Meethal Shibukumar
Journal: The Lancet Psychiatry (2019)
Good medical care is caring
Authors: W. R. Barclay
Journal: JAMA (1978)

Infrequently is an article written by a patient or member of a patient's family published inThe Journal. However, the contribution from Mary Kate House in this issue (p 2472) is an exception, for it is filled with wisdom and sound practical advice. She describes ideal care for the elderly and chronically ill in the environment of the patient's home, with devoted ministrations from the family members and friends. No nursing home, no staff of experts, and no government health scheme can provide the quality of care described in this article. Medical care is more than the application of technology and knowledge. It is, first of all, caring, and this component of medicine seems to be missing from much of what we do today. Most neglected in this respect are the elderly ill and the incurable. Placed in long-term care facilities, they are often neglected by their physicians and their
Gut microbiota dysbiosis
Authors: C. Hidalgo‐Cantabrana, J. Gómez, S. Delgado, S. Requena‐López, R. Queiro‐Silva, A. Margolles, E. Coto, B. Sánchez, P. Coto‐Segura
Journal: British Journal of Dermatology (2019)

Human beings and other animals live with a complex mixture of different bacteria (called microbiota) on the skin and in the gut, and these micro‐organisms play an important role in helping us to remain healthy.
XMEN: welcome to the glycosphere
Authors: Hudson H. Freeze
Journal: Journal of Clinical Investigation (2019)

XMEN (X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia) is a complex primary immunological deficiency caused by mutations in MAGT1, a putative magnesium transporter. In this issue of the JCI, Ravell et al. greatly expand the clinical picture. The authors investigated patients' mutations and symptoms and reported distinguishing immunophenotypes. They also showed that MAGT1 is required for N-glycosylation of key T cell and NK cell receptors that can account for some of the clinical features. Notably, transfection of the affected lymphocytes with MAGT1 mRNA restored both N-glycosylation and receptor function. Now we can add XMEN to the ever-growing family of congenital disorders of glycosylation (CDG).